Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H17N3O5.K.H |
| Molecular Weight | 371.4295 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[K+].N[C@H](CCC(=O)N[C@H](CC1=CNC2=C1C=CC=C2)C([O-])=O)C([O-])=O
InChI
InChIKey=JBUWHGCMOSDECA-LOCPCMAASA-M
InChI=1S/C16H19N3O5.K/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12;/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24);/q;+1/p-1/t11-,13-;/m1./s1
Orilotimod (previously known as Apo 805K1), an antipsoriatic agent that was studied for the treatment of moderate to severe plaque psoriasis. This drug successfully completed phase II clinical trial in the USA. However, information about the further development of this drug is not available.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Q8858ZSK4Y
Created by
admin on Sat Dec 16 09:09:56 GMT 2023 , Edited by admin on Sat Dec 16 09:09:56 GMT 2023
|
PRIMARY | |||
|
960155-19-5
Created by
admin on Sat Dec 16 09:09:56 GMT 2023 , Edited by admin on Sat Dec 16 09:09:56 GMT 2023
|
PRIMARY | |||
|
24849212
Created by
admin on Sat Dec 16 09:09:56 GMT 2023 , Edited by admin on Sat Dec 16 09:09:56 GMT 2023
|
PRIMARY | |||
|
C174878
Created by
admin on Sat Dec 16 09:09:56 GMT 2023 , Edited by admin on Sat Dec 16 09:09:56 GMT 2023
|
PRIMARY | |||
|
300000044582
Created by
admin on Sat Dec 16 09:09:56 GMT 2023 , Edited by admin on Sat Dec 16 09:09:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL3137306
Created by
admin on Sat Dec 16 09:09:56 GMT 2023 , Edited by admin on Sat Dec 16 09:09:56 GMT 2023
|
PRIMARY | |||
|
AB-04
Created by
admin on Sat Dec 16 09:09:56 GMT 2023 , Edited by admin on Sat Dec 16 09:09:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
